1 |
ClinicalTrials.gov (NCT02013167) Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
|
2 |
Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies. Hum Vaccin Immunother. 2019;15(3):594-602.
|
3 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
4 |
2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
|
5 |
2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
|
6 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
|
7 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
|
8 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
|
9 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
|
10 |
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
|
11 |
Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021 Jan 14;17:39-54.
|
12 |
A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
|
13 |
ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL
|
14 |
ClinicalTrials.gov (NCT03391726) CART-19 Cells for R/R B-cell Lymphoma
|
15 |
Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
|
16 |
Clinical pipeline report, company report or official report of Genmab.
|
17 |
FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
|
18 |
FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
|
19 |
Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
|
20 |
Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
|
21 |
Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
|
22 |
Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
|
23 |
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.
|
24 |
ClinicalTrials.gov (NCT05220098) A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer. U.S.National Institutes of Health.
|
|
|
|
|
|
|